Home
>
US Stocks
>
Myovant Sciences Ltd
Myovant Sciences Ltd
MYOV

Myovant Sciences Ltd (MYOV)

$20.697.8%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
20.35
Today Low/High
20.35 / 21.13
52 Week Low/High
$13.42 / $30.9
Market Cap
$1.96B

Company Details

Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.
Organisation
Myovant Sciences Ltd
Employees
407
Industry
Health Technology

Discover more

Frequently Asked Questions

What is Myovant Sciences Ltd (MYOV) share price today?

Can Indians buy Myovant Sciences Ltd (MYOV) shares?

How can I buy Myovant Sciences Ltd (MYOV) shares from India?

Can Fractional shares of Myovant Sciences Ltd (MYOV) be purchased?

What are the documents required to start investing in Myovant Sciences Ltd (MYOV) stocks?

We are a SEBI registered investement advisor